Del(1p32): prime time in (ultra) high-risk myeloma

Ajay K. Nooka, Efstathios Kastritis, Jonathan L. Kaufman, Maria Gavriatopoulou, Lawrence Boise, Μαρία Ρούσσου, Dhwani Almaula, David L. Jaye, Evangelos Terpos, Sagar Lonial, Meletios A Dimopoulos

Article2022

Chromosome 1q21 aberrations identify ultra <scp>high‐risk</scp> myeloma with prognostic and clinical implications

Efstathios Kastritis, Magdalini Migkou, Dimitra Dalampira, Maria Gavriatopoulou, Despina Fotiou, Μαρία Ρούσσου, Nikolaos Kanellias, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Foteini Theodorakakou, Aggeliki Sevastoudi, Evangelos Eleutherakis‐Papaiakovou, Theodora Triantafyllou, Evangelos Terpos, Eirini Katodritou, Meletios A Dimopoulos

Del(1p32): prime time in (ultra) high-risk myeloma

Related publications

Denosumab for myeloma bone disease: ready for prime time?

Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia &amp; New Zealand Myeloma and Related Diseases Registry (MRDR)

Discussion(0)

Prime time for microbes

Clinical Characteristics and Outcomes of Myeloma Patients Exhibiting Translocation (14;16): An Ultra-High-Risk Group of Myeloma Patients

Chromosome 1q21 aberrations identify ultra <scp>high‐risk</scp> myeloma with prognostic and clinical implications

Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia & New Zealand Myeloma and Related Diseases Registry (MRDR)